Anzeige
Erschienen in:
01.05.2022 | Original Research Article
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus
Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 3/2022
Einloggen, um Zugang zu erhaltenAbstract
Background
Comorbid heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (DM) is associated with a very high risk of HF events. Sacubitril–valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), and dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, improve HF outcomes in these patients, but their comparative value for money in this patient population has not yet been determined.
Objective
We aimed to compare the cost needed to treat (CNT) to avoid an HF event with each drug.
Methods
CNT was estimated by multiplying the annualized number needed to treat (NNT) to prevent one HF event by the annual cost of each therapy. HF events were defined as the first event of hospitalization for HF or cardiovascular mortality. Drug efficacy data were extracted from published secondary analyses of patients with DM in the DAPA-HF and PARADIGM-HF trials. Drug costs were estimated as 75% of the 2021 US National Average Drug Acquisition Cost listing. Sensitivity analysis was performed on parameters that may have affected the CNT.
Results
The annualized NNT was 24 (95% confidence interval [CI] 16–54) for dapagliflozin and 57 (95% CI 31–433) for the ARNI. At an annual cost of $US4523 and 5099, respectively, the CNT was $US108,563 (95% CI 72,375–244,267) for dapagliflozin and $US290,671 (95% CI 158,084–2,208,079) for the ARNI.
Conclusions
Dapagliflozin seems to offer greater value for money than the ARNI for patients with HFrEF and DM. Our results provide support for contemporary guidelines advocating the use of dapagliflozin in these patients.